Integrated Biopharma, Inc.
INBP
$0.3069
$0.01194.03%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -55.21% | -3.36% | -5.96% | 174.61% | -547.46% |
| Total Depreciation and Amortization | -0.63% | 0.95% | 4.28% | 0.66% | 1.34% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -50.59% | 82.01% | -2.11% | 1,677.78% | -110.98% |
| Change in Net Operating Assets | -104.57% | 80.77% | -199.78% | 152.47% | -275.20% |
| Cash from Operations | -69.41% | 453.23% | -111.32% | 189.93% | -239.15% |
| Capital Expenditure | 48.21% | 61.64% | 57.68% | -1,337.50% | 36.84% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 48.21% | 61.64% | 57.68% | -1,337.50% | 36.84% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | 36.36% | -10.00% | 9.09% | -10.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 357.14% | 36.36% | -10.00% | 9.09% | -466.67% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -68.01% | 273.18% | -126.63% | 169.17% | -245.70% |
